Hong Kong
Search
Sign In
Change Password
Points
Sign Out
Obstetrics & Gynaecology
Sacituzumab govitecan improved progression-free survival (PFS) and overall survival (OS) in Asian patients with HR+/HER2– metastatic breast cancer (mBC) compared with the treatment of physician’s choice (TPC*), according to the EVER-132-002 study presented at ESMO Asia 2023.
Cervical length as measured by transperineal ultrasound can predict preterm delivery in women with threatened preterm labour, according to results of a retrospective observational study in 60 Hong Kong women.
Dr Heidi Leung, Specialist in Obstetrics & Gynaecology in private practice in Hong Kong, talks to MIMS Doctor ahead of World Contraception Day (WCD) on 26 September 2023, discussing contraception practices in Hong Kong, dispelling some of the common myths surrounding oral contraceptive pills and providing practical advice on their use.
The patient is a 39-year-old female who was diagnosed with systemic lupus erythematosus (SLE) in 2015 and initially presented with significant proteinuria (24-hour urine total protein, 6.6 g). Renal biopsy confirmed class II and V lupus nephritis (LN). Further laboratory investigations were consistent with SLE, including positive antinuclear antibodies (ANA), high anti-double stranded DNA (anti-dsDNA) level (>1000 IU/L), and positive lupus anticoagulant. Complement testing showed low levels of C3 and C4, suggestive of active disease.1
International antiemetic guidelines recommend combination regimens, such as a corticosteroid plus a serotonin (5-HT3) receptor antagonist (RA) with or without a neurokinin-1 (NK1) RA, as standard of care for prevention of chemotherapy-induced nausea and vomiting (CINV). However, despite the availability of various antiemetic agents and combinations, some patients still experience severe CINV that may hinder cancer treatment adherence. At a symposium organized by the Macau Oncology Association, Professor Roger Ngan of the Department of Clinical Oncology, University of Hong Kong, and Dr Cheng-Vai Hui, Consultant in Medical Oncology, Macau Oncology Association, discussed recent updates in clinical guidelines on CINV management and shared their experience in CINV prophylaxis using a fixed oral combination of an NK1 RA and a 5-HT3 RA (netupitant/palonosetron [NEPA]) in cancer patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC).
Sacituzumab govitecan improved progression-free survival (PFS) and overall survival (OS) in Asian patients with HR+/HER2– metastatic breast cancer (mBC) compared with the treatment of physician’s choice (TPC*), according to the EVER-132-002 study presented at ESMO Asia 2023.
